Keyword: Jardiance

Former Eli Lilly CFO Derica Rice becomes the second top Big Pharma ex to take the reins at a major pharmacy benefit manager.

When it comes to real-world heart benefits, SGLT2 diabetes drugs continue to impress—this time with reduced risks of heart attack and stroke.

Lilly and BI are gunning for a heart-failure nod for Jardiance. And they want to be able to talk up the drug’s effects on exercise ability, too.

Novo Nordisk's newest Victoza campaign doubles down on its approved trifecta of preventative indications for heart attack, stroke and CV death.

Eli Lilly is wasting no time looking for growth avenues for GLP-1 contender Trulicity. And if new data are any indication, it may have just found one.

Eli Lilly and Livongo team up to tap real-world data to help diabetes patients adopt healthier habits and save money—and boost treatment results, too.

Prime Therapeutics plans to examine the total healthcare costs for Boehringer Ingelheim's SGLT2 drug Jardiance versus the competition.

Eli Lilly is aiming for $23 billion in 2018 revenue, but it'll have to contend with a tough environment in diabetes and one hefty patent expiration.

A new study shows SGLT2 diabetes drugs can cut the rate of major cardiovascular events in patients new to treatment.

After a rare decline last month, AbbVie's Humira reclaimed its title as top advertised drug on TV with more than $40 million in spending.